Table 2.
Baseline characteristics of the study population
| N = 3 858 335 | ||
|---|---|---|
| Number of individuals included in each study year (n) | ||
| 2016 | 3 529 035 | |
| 2017 | 3 406 005 | |
| 2018 | 3 336 317 | |
| 2019 | 3 248 735 | |
| Age (years) at study entry | ||
| Mean (Minimum, maximum) | 47 | (16–108) |
| Age group (years) at study entry (n, %) | ||
| 16–49 | 2 086 526 | 54.08 |
| 50–59 | 680 237 | 17.63 |
| 60–69 | 467 343 | 12.11 |
| ≥70 | 624 229 | 16.18 |
| Sex (n, %) | ||
| Male | 1 892 342 | 49.05 |
| Female | 1 965 993 | 50.95 |
| Presence of at-risk medical condition in the pre-period (n, %) | ||
| No history of at-risk or high-risk medical condition | 1 539 526 | 39.90 |
| History of any at-risk medical condition | 2 178 167 | 56.45 |
| Chronic diseases | ||
| Diabetes mellitus | 486 205 | 12.60 |
| Chronic pulmonary disease (incl. asthma) | 1 039 525 | 26.94 |
| Chronic heart disease | 1 576 945 | 40.87 |
| Neurological disorders | 128 109 | 3.32 |
| Any high-risk medical condition | 728 198 | 18.87 |
| Cancer | 247 337 | 6.41 |
| Cerebrospinal fluid leak | 951 | 0.02 |
| Chronic renal disease | 200 377 | 5.19 |
| Cochlear implant | 5837 | 0.15 |
| Functional or anatomic asplenia, sickle cell disease/other hemaglobinopathy, congenital or acquired asplenia, splenic dysfunction, splenectomy | 17 887 | 0.46 |
| HIV infection | 4008 | 0.10 |
| Immuno-compromising diseases | 113 710 | 2.95 |
| Organ transplant | 20 492 | 0.53 |
| Chronic liver disease | 202 125 | 5.24 |
| Autoimmune disease | 100 505 | 2.60 |